help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on July 24, 2003
Endocrinology, doi:10.1210/en.2003-0035
A more recent version of this article appeared on November 1, 2003
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
144/11/4841    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woodham, C.
Right arrow Articles by Prins, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woodham, C.
Right arrow Articles by Prins, G. S.

Submitted on January 8, 2003
Accepted on July 14, 2003

NEONATAL ESTROGEN DOWN REGULATES PROSTATIC ANDROGEN RECEPTOR THROUGH A PROTEOSOME-MEDIATED PROTEIN DEGRADATION PATHWAY

Carl Woodham1, Lynn Birch1, and Gail S. Prins1*

1 Department of Urology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612

* To whom correspondence should be addressed. E-mail: gprins{at}uic.edu.

Brief exposure of male rats to estrogens during the neonatal period interrupts normal prostate development, alters epithelial cell differentiation and predisposes this gland to hyperplasia and severe dysplasia analogous to prostatic intraepithelial neoplasia (PIN) with aging. Previous work demonstrated that the reduced growth, secretory activity and androgen sensitivity that are observed in the adult ventral lobe are a function of reduced androgen receptor (AR) levels. Down-regulation of AR protein was found to occur immediately following neonatal exposure to estradiol benzoate (EB) and persist through adulthood and aging indicating a permanent imprint on the ability of the prostate to express normal AR levels. To determine the intracellular mechanism of AR down regulation by estrogens, the present study examined the effect of neonatal EB on AR gene transcription, mRNA levels, protein translation and protein degradation in the day 10 ventral prostate glands. Nuclear run-on assays showed no alteration in AR gene transcription following exposure to EB on days 1-5 compared with controls. In situ hybridization and qRT-PCR revealed no difference in mRNA levels in the stromal or epithelial cells in response to estrogen exposure which, taken together, indicate that estrogen down regulation of AR is mediated at the post-transcriptional level. AR translation was assessed with an in vitro transcription-translation assay in the presence of prostatic lysates from oil and estrogen-exposed animals and no treatment affect was noted. AR degradation was examined in an in vitro assay validated with adult intact and castrate prostates. Prostatic lysates from intact rats initiated AR degradation with a t1/2 of 2.31 h whereas proteins from castrate rats accelerated AR degradation to a t1/2 of 1.34 h (P < 0.001). Prostatic lysates from control day 10 prostates induced AR degradation with a t1/2 of 1.49 h while estrogenized prostates increased AR degradation to a t1/2 of 1.11 h (P < 0.001). Proteosome inhibitors MG132 and ALLnL were able to reverse AR degradation induced by prostatic lysates from adult intact and castrate rats as well as from developing and estrogenized prostates indicating that AR degradation was mediated through the proteosome pathway. Furthermore, the proteosome-mediated AR degradation in the estrogenized day 10 prostate was associated with a marked suppression of Akt phosphorylation which has been linked to AR degradation in other systems. Taken together, the present data show that exposure to neonatal estrogens down-regulates AR protein levels in the ventral prostate gland by accelerating AR degradation which is mediated through the proteosome pathway.


Key words: prostate • estradiol • estrogen • rogen receptor • proteosome







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society